跳至主要内容
临床试验/NCT05264051
NCT05264051招募中不适用

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

University of Chicago1 个研究点 分布在 1 个国家目标入组 1,200 人开始时间: 2022年4月18日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
1,200
试验地点
1
主要终点
Waitlist Mortality

研究概览

简要总结

The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.

详细描述

Prospective study of patients seen at the Univ. of Chicago Medical Center hospital and ambulatory clinics. The assessment of the MAsS score will require an additional 8-10 minutes in the MRI for each patient already undergoing MRI exam.

Four groups of pts. who are already scheduled for MRI for routine clinical purposes will be evaluated.

  1. Pts. hospitalized with acute hepatic decompensation for whom MRI is otherwise indicated for clinical evaluation.
  2. Pts. with hepatobiliary neoplasia
  3. Pts.undergoing transjugular portosystemic shunt (TIPS) placement
  4. Pts. with chronic liver disease undergoing magnetic resonance elastography for routine monitoring

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated

排除标准

  • <18 yrs. of age

结局指标

主要结局

Waitlist Mortality

时间窗: Measured up to 10 years out from enrollment

Death prior to liver transplant or delisting from enrollment in the study

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验